December 19, 2013
06:22 EDT RTRX Retrophin added to Focus List, target to $41 at Roth Capital
Roth Capital added Retrophin to the Focus List following the announcement of new clinical candidate RE-034, a synthetic peptide of natural hormone. The firm views the news as another pipeline boost, increasing its CNS and nephrology focus. Price target raised to $41 from $15.
roth used to cover qcor, but due to declining reves, they've lost 2/3 of their research analysts the past year and now only "cover" stocks where they hope to have banking relationships to raise money for them. most institutions have bailed on roth and their annual conference has been in decline for several years now. as for their price target, i don't think it means anything as everyone knows it's just for banking positioning.